Open AccessCoccidioidomycosis and COVID-19 Infection. An Analysis from a Single Medical Center Within the Coccidioidal Endemic Area
Author(s) -
Daniel Huff,
Neil M. Ampel,
Janis E. Blair
Publication year - 2022
Publication title -
mycopathologia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.744
H-Index - 73
eISSN - 1573-0832
pISSN - 0301-486X
DOI - 10.1007/s11046-022-00629-6
Subject(s) - medical microbiology , covid-19 , medicine , cohort , single center , immunology , disease , infectious disease (medical specialty)
At a single medical center, we identified 60 cases of coccidioidomycosis that were coincident with COVID-19 infection. Among these, seven patients developed new or clinically progressive coccidioidomycosis. Receipt of dexamethasone for COVID-19 infection was the only significant risk factor for the progression or development of clinically active coccidioidomycosis in this cohort. All patients survived and none developed disseminated coccidioidomycosis.